Compare STMicroelectronics NV (STM) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
STMicroelectronics NV vs 10X Genomics Inc — how do they compare? STMicroelectronics NV trades at $51.68 (market cap $46.67B), while 10X Genomics Inc trades at $67.8 (market cap $8.55B). The key difference: STMicroelectronics NV is far larger — about 5.5× 10X Genomics Inc's market cap, and STMicroelectronics NV pays a 0.69% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| STM | TXG | |
|---|---|---|
Market Cap | $46.67B | $8.55B |
Sector | Financials | Health |
52-Week High | $79.91 | $67.29 |
52-Week Low | $21.20 | $11.34 |
Enterprise Value | $44.19B | $8.08B |
Dividend Yield | 0.69% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
STM trades at $51.97, down 0.52% today, with a bullish technical outlook supported by moving averages and key support at $52. The company shows mixed fundamentals with a high P/E of 98.84 but strong cash flow generation of $555M in 2025. Recent news highlights AI datacenter revenue targets exceeding $2B by 2027, positioning STM for growth in industrial automation and edge AI markets.
STM faces near-term margin pressures with negative net income margin but offers significant upside to the $71.83 analyst consensus target. Key risks include execution on AI growth targets and semiconductor cycle volatility. The bullish analyst consensus (52% buy ratings) suggests confidence in the company's strategic positioning despite current profitability challenges.
TXG trades at $65.60, up 4.71% today, with strong technical momentum showing bullish moving averages and key support at $63. Fundamentally, the company demonstrates improving trends with Q2 2026 earnings beating estimates and revenue growth guidance raised, though profitability remains negative with a -12.18% net margin. Recent patent victory against Parse Biosciences strengthens competitive positioning.
The outlook remains cautiously optimistic with analyst consensus at 45% buy ratings and $50.78 price target. Key opportunities include Atera platform adoption and consumables growth, while risks center on valuation premiums and ongoing profitability challenges. The stock trades near resistance at $67 with institutional interest showing mixed signals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About STMicroelectronics NV
A merger between Italian firm SGS Microelettronica and the nonmilitary business of Thomson Semiconductors in France formed STMicroelectronics in 1987. STMicro is a leader in a variety of semiconductor products, including analog chips, discrete power semiconductors, microcontrollers, and sensors. STMicro is an especially prominent chip supplier into the industrial and automotive industries.
Read more on STM →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
